{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T11:07:11Z","timestamp":1793963231702,"version":"4.8.0"},"reference-count":148,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["international-journal-of-gynecological-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Gynecological Cancer"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.ijgc.2025.101992","type":"journal-article","created":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T03:11:08Z","timestamp":1751425868000},"page":"101992","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Uterine leiomyosarcoma"],"prefix":"10.1016","volume":"35","author":[{"given":"Giorgio","family":"Bogani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5501-1936","authenticated-orcid":false,"given":"Giuseppe","family":"Caruso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Ray-Coquard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro T.","family":"Ramirez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Concin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie YL.","family":"Ngoi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert L.","family":"Coleman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8059-1602","authenticated-orcid":false,"given":"Andrea","family":"Mariani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Cliby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0818-3836","authenticated-orcid":false,"suffix":"Jr.","given":"Mario M.","family":"Leitao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadeem Abu","family":"Rustum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo G.","family":"Casali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4703-3534","authenticated-orcid":false,"given":"Alessandro","family":"Gronchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7589-8981","authenticated-orcid":false,"given":"Ignace","family":"Vergote","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2671-1903","authenticated-orcid":false,"given":"Judith","family":"Kroep","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4538-5541","authenticated-orcid":false,"given":"Takayuki","family":"Enomoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8808-3338","authenticated-orcid":false,"given":"Kazuhiro","family":"Takehara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannelore","family":"Denys","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masashi","family":"Takano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane","family":"Provencher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7380-577X","authenticated-orcid":false,"given":"Pauline","family":"Wimberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Se Ik","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1835-9436","authenticated-orcid":false,"given":"Jae-Weon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gian Franco","family":"Zannoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David SP.","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jvan","family":"Casarin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Biagio","family":"Paolini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Chiappa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Raspagliesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilaria","family":"Cuccu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Violante","family":"Di Donato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"O'Malley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6921-1581","authenticated-orcid":false,"given":"David","family":"Mutch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jubilee","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernanda","family":"Herrera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicoletta","family":"Colombo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandro","family":"Pignata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Scambia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian M.","family":"Slomovitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6985-0159","authenticated-orcid":false,"given":"Bradley J.","family":"Monk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.ijgc.2025.101992_bib1","doi-asserted-by":"crossref","first-page":"2922","DOI":"10.1002\/ijc.22239","article-title":"Incidence patterns of soft tissue sarcomas, regardless of primary site, in the surveillance, epidemiology and end results program, 1978\u20132001: an analysis of 26,758 cases","volume":"119","author":"Toro","year":"2006","journal-title":"Int J Cancer"},{"issue":"1","key":"10.1016\/j.ijgc.2025.101992_bib2","first-page":"17","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J Clin"},{"issue":"6","key":"10.1016\/j.ijgc.2025.101992_bib3","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1097\/IGC.0000000000000720","article-title":"Uterine sarcoma: analysis of 13,089 cases based on surveillance, epidemiology, and end results database","volume":"26","author":"Hosh","year":"2016","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.ijgc.2025.101992_bib4","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1200\/EDBK_350541","article-title":"Novel therapeutics in the treatment of uterine sarcoma","volume":"42","author":"Bose","year":"2022","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"1","key":"10.1016\/j.ijgc.2025.101992_bib5","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ygyno.2020.08.008","article-title":"State of the science: uterine sarcomas: from pathology to practice","volume":"159","author":"Shushkevich","year":"2020","journal-title":"Gynecol Oncol"},{"issue":"10","key":"10.1016\/j.ijgc.2025.101992_bib6","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1136\/ijgc-2024-005823","article-title":"ESGO\/EURACAN\/GCIG guidelines for the management of patients with uterine sarcomas","volume":"34","author":"Ray-Coquard","year":"2024","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.ijgc.2025.101992_bib7","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/3561501","article-title":"Adjuvant chemotherapy in uterine leiomyosarcoma: trends and factors impacting usage","volume":"2019","author":"Patel","year":"2019","journal-title":"Sarcoma"},{"issue":"1","key":"10.1016\/j.ijgc.2025.101992_bib8","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ygyno.2017.02.012","article-title":"Prognosis and treatment of uterine leiomyosarcoma: a National Cancer Database study","volume":"145","author":"Seagle","year":"2017","journal-title":"Gynecol Oncol"},{"issue":"1","key":"10.1016\/j.ijgc.2025.101992_bib9","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ygyno.2017.07.122","article-title":"Adjuvant gemcitabine-docetaxel chemotherapy for stage I uterine leiomyosarcoma: trends and survival outcomes","volume":"147","author":"Littell","year":"2017","journal-title":"Gynecol Oncol"},{"issue":"11","key":"10.1016\/j.ijgc.2025.101992_bib10","doi-asserted-by":"crossref","first-page":"2637","DOI":"10.1002\/cncr.32795","volume":"126","author":"D\u2019Ambrosio","year":"2020","journal-title":"Cancer"},{"issue":"9","key":"10.1016\/j.ijgc.2025.101992_bib11","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1111\/aogs.12930","article-title":"Uterine leiomyosarcoma - incidence, treatment, and the impact of morcellation. A nationwide cohort study","volume":"95","author":"Skorstad","year":"2016","journal-title":"Acta Obstet Gynecol Scand"},{"issue":"11","key":"10.1016\/j.ijgc.2025.101992_bib12","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1097\/00000478-199711000-00001","article-title":"Bizarre leiomyomas of the uterus: a comprehensive pathologic study of 24 cases with long-term follow-up","volume":"21","author":"Downes","year":"1997","journal-title":"Am J Surg Pathol"},{"issue":"3","key":"10.1016\/j.ijgc.2025.101992_bib13","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1136\/jcp.56.3.233","article-title":"Soft tissue, pelvic, and urinary bladder leiomyosarcoma as second neoplasm following hereditary retinoblastoma","volume":"56","author":"Venkatraman","year":"2003","journal-title":"J Clin Pathol."},{"issue":"5","key":"10.1016\/j.ijgc.2025.101992_bib14","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1002\/cncr.26390","article-title":"Sarcomas in TP53 germline mutation carriers: a review of the IARC TP53 database","volume":"118","author":"Ognjanovic","year":"2012","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.ijgc.2025.101992_bib15","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/j.ygyno.2018.09.010","article-title":"Uterine leiomyosarcoma: a review of the literature and update on management options","volume":"151","author":"Roberts","year":"2018","journal-title":"Gynecol Oncol"},{"issue":"2","key":"10.1016\/j.ijgc.2025.101992_bib16","first-page":"114","article-title":"Leiomyosarcoma of the uterus: ultrasonography and serum lactate dehydrogenase level","volume":"33","author":"Seki","year":"1992","journal-title":"Gynecol Obstet Invest"},{"issue":"11","key":"10.1016\/j.ijgc.2025.101992_bib17","first-page":"697","article-title":"CA125 expression in the tissue of uterine leiomyosarcoma","volume":"16","author":"Menczer","year":"2014","journal-title":"Isr Med Assoc J"},{"issue":"4","key":"10.1016\/j.ijgc.2025.101992_bib18","first-page":"370","article-title":"Potential role of preoperative serum CA125 for the differential diagnosis between uterine leiomyoma and uterine leiomyosarcoma","volume":"27","author":"Juang","year":"2006","journal-title":"Eur J Gynaecol Oncol."},{"issue":"3","key":"10.1016\/j.ijgc.2025.101992_bib19","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/S0090-8258(03)00137-9","article-title":"Retrospective review of 208 patients with leiomyosarcoma of the uterus: prognostic indicators, surgical management, and adjuvant therapy","volume":"89","author":"Giuntoli","year":"2003","journal-title":"Gynecol Oncol"},{"issue":"1","key":"10.1016\/j.ijgc.2025.101992_bib20","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.ygyno.2009.09.023","article-title":"Uterine sarcomas: a review","volume":"116","author":"D\u2019Angelo","year":"2010","journal-title":"Gynecol Oncol"},{"issue":"7","key":"10.1016\/j.ijgc.2025.101992_bib21","doi-asserted-by":"crossref","first-page":"2903","DOI":"10.1007\/s00330-016-4623-9","article-title":"Differentiation of uterine leiomyosarcoma from atypical leiomyoma: diagnostic accuracy of qualitative MR imaging features and feasibility of texture analysis","volume":"27","author":"Lakhman","year":"2017","journal-title":"Eur Radiol"},{"issue":"2","key":"10.1016\/j.ijgc.2025.101992_bib22","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1111\/IGC.0b013e31819a1f8f","article-title":"Uterine leiomyosarcoma: does the primary surgical procedure matter?","volume":"19","author":"Perri","year":"2009","journal-title":"Int J Gynecol Cancer"},{"issue":"3","key":"10.1016\/j.ijgc.2025.101992_bib23","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.ygyno.2014.03.001","article-title":"Adjuvant chemotherapy in stage I\u2013II uterine leiomyosarcoma: a multicentric retrospective study of 140 patients","volume":"133","author":"Mancari","year":"2014","journal-title":"Gynecol Oncol"},{"issue":"2","key":"10.1016\/j.ijgc.2025.101992_bib24","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.ygyno.2016.07.110","article-title":"Efficacy of adjuvant chemotherapy in early stage uterine leiomyosarcoma: a systematic review and meta-analysis","volume":"143","author":"Bogani","year":"2016","journal-title":"Gynecol Oncol"},{"issue":"4","key":"10.1016\/j.ijgc.2025.101992_bib25","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1002\/cncr.2820710440","article-title":"Prognostic factors in early-stage uterine sarcoma. A Gynecologic Oncology Group study","volume":"71","author":"Major","year":"1993","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.ijgc.2025.101992_bib26","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1002\/cncr.23245","article-title":"Prognostic factors and survival in 1396 patients with uterine leiomyosarcomas: emphasis on impact of lymphadenectomy and oophorectomy","volume":"112","author":"Kapp","year":"2008","journal-title":"Cancer"},{"issue":"12","key":"10.1016\/j.ijgc.2025.101992_bib27","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1200\/JCO.2008.19.8366","article-title":"Stage-specific outcomes of patients with uterine leiomyosarcoma: a comparison of the international Federation of gynecology and obstetrics and American Joint Committee on Cancer staging systems","volume":"27","author":"Zivanovic","year":"2009","journal-title":"J Clin Oncol."},{"issue":"1","key":"10.1016\/j.ijgc.2025.101992_bib28","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1097\/PGP.0000000000000284","article-title":"Distant metastases in uterine leiomyosarcomas: the wide variety of body sites and time intervals to metastatic relapse","volume":"36","author":"Bartosch","year":"2017","journal-title":"Int J Gynecol Pathol"},{"key":"10.1016\/j.ijgc.2025.101992_bib29","doi-asserted-by":"crossref","first-page":"4657","DOI":"10.2147\/CMAR.S302223","article-title":"Diagnostic value of preoperative CA125, LDH and HE4 for leiomyosarcoma of the female reproductive system","volume":"13","author":"Zhang","year":"2021","journal-title":"Cancer Manag Res"},{"issue":"1","key":"10.1016\/j.ijgc.2025.101992_bib30","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1186\/s12885-018-5156-1","article-title":"Management of uterine sarcomas and prognostic indicators: real world data from a single-institution","volume":"18","author":"Kyriazoglou","year":"2018","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1016\/j.ijgc.2025.101992_bib31","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1186\/s12905-018-0662-5","article-title":"Increased LDH5\/LDH1 ratio in preoperative diagnosis of uterine sarcoma with inconclusive MRI and LDH total activity but suggestive CT scan: a case report","volume":"18","author":"Mollo","year":"2018","journal-title":"BMC Womens Health"},{"issue":"10","key":"10.1016\/j.ijgc.2025.101992_bib32","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.diii.2019.07.007","article-title":"How to differentiate uterine leiomyosarcoma from leiomyoma with imaging","volume":"100","author":"Sun","year":"2019","journal-title":"Diagn Interv Imaging"},{"key":"10.1016\/j.ijgc.2025.101992_bib33","article-title":"Comparison of the diagnostic accuracy of contrast-enhanced\/DWI MRI and ultrasonography in the differentiation between benign and malignant myometrial tumors","volume":"70","author":"Najibi","year":"2021","journal-title":"Ann Med Surg (Lond)."},{"issue":"2","key":"10.1016\/j.ijgc.2025.101992_bib34","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1136\/ijgc-2023-004880","article-title":"Uterine smooth muscle tumors: a multicenter, retrospective, comparative study of clinical and ultrasound features","volume":"34","author":"Borella","year":"2024","journal-title":"Int J Gynecol Cancer"},{"issue":"5","key":"10.1016\/j.ijgc.2025.101992_bib35","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1002\/uog.20270","article-title":"Imaging in gynecological disease (15): clinical and ultrasound characteristics of uterine sarcoma","volume":"54","author":"Ludovisi","year":"2019","journal-title":"Ultrasound Obstet Gynecol"},{"issue":"2","key":"10.1016\/j.ijgc.2025.101992_bib36","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1002\/jmri.24998","article-title":"Comparison of the diagnostic accuracy of contrast-enhanced MRI and diffusion-weighted MRI in the differentiation between uterine leiomyosarcoma \/ smooth muscle tumor with uncertain malignant potential and benign leiomyoma","volume":"43","author":"Lin","year":"2016","journal-title":"J Magn Reson Imaging"},{"issue":"1","key":"10.1016\/j.ijgc.2025.101992_bib37","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1002\/ijgo.15136","article-title":"Diagnostic accuracy of MRI in the differential diagnosis between uterine leiomyomas and sarcomas: a systematic review and meta-analysis","volume":"165","author":"Raffone","year":"2024","journal-title":"Int J Gynecol Obstet"},{"issue":"3","key":"10.1016\/j.ijgc.2025.101992_bib38","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.ijgo.2008.12.008","article-title":"FIGO staging for uterine sarcomas","volume":"104","author":"Prat","year":"2009","journal-title":"Int J Gynecol Obstet"},{"key":"10.1016\/j.ijgc.2025.101992_bib39","series-title":"AJCC Cancer Staging Manual","author":"Edge","year":"2010"},{"issue":"8","key":"10.1016\/j.ijgc.2025.101992_bib40","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1097\/IGC.0b013e3182a20e18","article-title":"Diagnostic performance of fluorine-18-fluorodeoxyglucose positron emission tomography imaging in uterine sarcomas: systematic review and meta-analysis of the literature","volume":"23","author":"Sadeghi","year":"2013","journal-title":"Int J Gynecol Cancer"},{"issue":"3","key":"10.1016\/j.ijgc.2025.101992_bib41","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/j.ygyno.2021.04.004","article-title":"Using rADioMIcs and machine learning with ultrasonography for the differential diagnosis of myometRiAL tumors (the ADMIRAL pilot study). Radiomics and differential diagnosis of myometrial tumors","volume":"161","author":"Chiappa","year":"2021","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ijgc.2025.101992_bib42","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.946022","article-title":"Application of multi-omics approach in sarcomas: a tool for studying mechanism, biomarkers, and therapeutic targets","volume":"12","author":"Zou","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.ijgc.2025.101992_bib43","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.ejogrb.2020.01.002","article-title":"Clinical experience of uterine smooth muscle tumor of uncertain malignant potential in two gynecological centers: oncological and obstetrical aspects","volume":"246","author":"Shim","year":"2020","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"10.1016\/j.ijgc.2025.101992_bib44","series-title":"WHO Classification of Tumours of Female Reproductive Organs","author":"Kurman","year":"2014"},{"issue":"5","key":"10.1016\/j.ijgc.2025.101992_bib45","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1097\/PAS.0b013e3182851162","article-title":"Interobserver variability in the interpretation of tumor cell necrosis in uterine leiomyosarcoma","volume":"37","author":"Lim","year":"2013","journal-title":"Am J Surg Pathol"},{"issue":"3","key":"10.1016\/j.ijgc.2025.101992_bib46","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1097\/PAS.0000000000000593","article-title":"Myxoid leiomyosarcoma of the uterus: a clinicopathologic analysis of 30 cases and review of the literature with reappraisal of its distinction from other uterine myxoid mesenchymal neoplasms","volume":"40","author":"Parra-Herran","year":"2016","journal-title":"Am J Surg Pathol"},{"issue":"4","key":"10.1016\/j.ijgc.2025.101992_bib47","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1097\/00000478-199704000-00003","article-title":"Epithelioid smooth-muscle tumors of the uterus: a clinicopathologic study of 18 patients","volume":"21","author":"Prayson","year":"1997","journal-title":"Am J Surg Pathol"},{"issue":"5","key":"10.1016\/j.ijgc.2025.101992_bib48","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1309\/JNQX-F4KM-Q0Q0-7XK8","article-title":"h-Caldesmon as a specific marker for smooth muscle tumors. Comparison with other smooth muscle markers in bone tumors","volume":"113","author":"Watanabe","year":"2000","journal-title":"Am J Clin Pathol"},{"issue":"6","key":"10.1016\/j.ijgc.2025.101992_bib49","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1002\/(SICI)1097-0142(20000315)88:6<1425::AID-CNCR21>3.0.CO;2-3","article-title":"Analysis of clinicopathologic prognostic factors for 157 uterine sarcomas and evaluation of a grading score validated for soft tissue sarcoma","volume":"88","author":"Pautier","year":"2000","journal-title":"Cancer"},{"issue":"17","key":"10.1016\/j.ijgc.2025.101992_bib50","doi-asserted-by":"crossref","first-page":"9728","DOI":"10.3390\/ijms23179728","article-title":"Molecular insights in uterine leiomyosarcoma: a systematic review","volume":"23","author":"Spari\u0107","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"3","key":"10.1016\/j.ijgc.2025.101992_bib51","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1080\/19396368.2021.1876179","article-title":"Molecular differential analysis of uterine leiomyomas and leiomyosarcomas through weighted gene network and pathway tracing approaches","volume":"67","author":"Sahly","year":"2021","journal-title":"Syst Biol Reprod Med"},{"issue":"6","key":"10.1016\/j.ijgc.2025.101992_bib52","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1038\/s41379-022-01011-z","article-title":"A novel morphology-based risk stratification model for stage I uterine leiomyosarcoma: an analysis of 203 cases","volume":"35","author":"Chapel","year":"2022","journal-title":"Mod Pathol"},{"issue":"11","key":"10.1016\/j.ijgc.2025.101992_bib53","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.6004\/jnccn.2015.0162","article-title":"Uterine sarcoma, version 1.2016: featured updates to the NCCN guidelines","volume":"13","author":"Koh","year":"2015","journal-title":"J Natl Compr Canc Netw"},{"issue":"9","key":"10.1016\/j.ijgc.2025.101992_bib54","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1200\/JCO.1985.3.9.1240","article-title":"A randomized clinical trial of adjuvant adriamycin in uterine sarcomas: a Gynecologic Oncology Group Study","volume":"3","author":"Omura","year":"1985","journal-title":"J Clin Oncol"},{"issue":"33","key":"10.1016\/j.ijgc.2025.101992_bib55","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.18.00454","article-title":"Adjuvant gemcitabine plus docetaxel followed by doxorubicin versus observation for high-grade uterine leiomyosarcoma: a phase III NRG oncology\/Gynecologic Oncology Group study","volume":"36","author":"Hensley","year":"2018","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.ijgc.2025.101992_bib56","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1002\/cncr.23592","article-title":"A systematic meta-analysis of randomized controlled trials of adjuvant chemotherapy for localized resectable soft-tissue sarcoma","volume":"113","author":"Pervaiz","year":"2008","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.ijgc.2025.101992_bib57","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.ygyno.2008.11.027","article-title":"Adjuvant gemcitabine plus docetaxel for completely resected stages I\u2013IV high grade uterine leiomyosarcoma: results of a prospective study","volume":"112","author":"Hensley","year":"2009","journal-title":"Gynecol Oncol"},{"issue":"8","key":"10.1016\/j.ijgc.2025.101992_bib58","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1002\/cncr.27942","article-title":"Adjuvant therapy for high-grade, uterus-limited leiomyosarcoma: results of a phase 2 trial (SARC 005)","volume":"119","author":"Hensley","year":"2013","journal-title":"Cancer"},{"issue":"10","key":"10.1016\/j.ijgc.2025.101992_bib59","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/S1470-2045(12)70346-7","article-title":"Adjuvant chemotherapy with doxorubicin, ifosfamide, and lenograstim for resected soft-tissue sarcoma (EORTC 62931): a multicentre randomised controlled trial","volume":"13","author":"Woll","year":"2012","journal-title":"Lancet Oncol"},{"issue":"12","key":"10.1016\/j.ijgc.2025.101992_bib60","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1093\/annonc\/mdu460","article-title":"Doxorubicin-based adjuvant chemotherapy in soft tissue sarcoma: pooled analysis of two STBSG-EORTC phase III clinical trials","volume":"25","author":"Le Cesne","year":"2014","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.ijgc.2025.101992_bib61","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1016\/j.ejca.2008.01.019","article-title":"Phase III randomised study to evaluate the role of adjuvant pelvic radiotherapy in the treatment of uterine sarcomas stages I and II: an European Organization for Research and Treatment of Cancer Gynaecological Cancer Group Study (protocol 55874)","volume":"44","author":"Reed","year":"2008","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.ijgc.2025.101992_bib62","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1006\/gyno.1996.0185","article-title":"Uterine leiomyosarcoma: analysis of treatment failures and survival","volume":"62","author":"Gadducci","year":"1996","journal-title":"Gynecol Oncol"},{"issue":"5","key":"10.1016\/j.ijgc.2025.101992_bib63","doi-asserted-by":"crossref","first-page":"536.e1","DOI":"10.1016\/j.ajog.2008.04.019","article-title":"The role of radiation in improving survival for early-stage carcinosarcoma and leiomyosarcoma","volume":"199","author":"Wright","year":"2008","journal-title":"Am J Obstet Gynecol"},{"issue":"6","key":"10.1016\/j.ijgc.2025.101992_bib64","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1111\/IGC.0b013e3181acae50","article-title":"Pelvic radiation improves local control after hysterectomy for uterine leiomyosarcoma: a 20-year experience","volume":"19","author":"Mahdavi","year":"2009","journal-title":"Int J Gynecol Cancer"},{"issue":"3","key":"10.1016\/j.ijgc.2025.101992_bib65","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.ijrobp.2009.02.077","article-title":"The role of adjuvant radiation in uterine sarcomas","volume":"76","author":"Sampath","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"10.1016\/j.ijgc.2025.101992_bib66","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1186\/s12885-019-5879-7","article-title":"Outcome of adjuvant radiotherapy after total hysterectomy in patients with uterine leiomyosarcoma or carcinosarcoma: a SEER-based study","volume":"19","author":"Li","year":"2019","journal-title":"BMC Cancer"},{"issue":"3","key":"10.1016\/j.ijgc.2025.101992_bib67","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.ygyno.2019.07.001","article-title":"Effect of adjuvant therapy on the risk of recurrence in early-stage leiomyosarcoma: a meta-analysis","volume":"154","author":"Chae","year":"2019","journal-title":"Gynecol Oncol"},{"issue":"4","key":"10.1016\/j.ijgc.2025.101992_bib68","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1093\/annonc\/mds545","article-title":"A randomized clinical trial of adjuvant chemotherapy with doxorubicin, ifosfamide, and cisplatin followed by radiotherapy versus radiotherapy alone in patients with localized uterine sarcomas (SARCGYN study). A study of the French Sarcoma Group","volume":"24","author":"Pautier","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ijgc.2025.101992_bib69","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/2045-3329-4-5","article-title":"Treatment of hormone positive uterine leiomyosarcoma with aromatase inhibitors","volume":"4","author":"Thanopoulou","year":"2014","journal-title":"Clin Sarcoma Res"},{"key":"10.1016\/j.ijgc.2025.101992_bib70","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s13569-020-00139-3","article-title":"Anthracycline-based and gemcitabine-based chemotherapy in the adjuvant setting for stage I uterine leiomyosarcoma: a retrospective analysis at two reference centers","volume":"10","author":"Fuc\u00e0","year":"2020","journal-title":"Clin Sarcoma Res."},{"issue":"6","key":"10.1016\/j.ijgc.2025.101992_bib71","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/j.bpobgyn.2011.06.003","article-title":"Role of chemotherapy and biomolecular therapy in the treatment of uterine sarcomas","volume":"25","author":"Hensley","year":"2011","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"issue":"9","key":"10.1016\/j.ijgc.2025.101992_bib72","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1056\/NEJMoa2403394","article-title":"Doxorubicin-trabectedin with trabectedin maintenance in leiomyosarcoma","volume":"391","author":"Pautier","year":"2024","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.ijgc.2025.101992_bib73","doi-asserted-by":"crossref","first-page":"921","DOI":"10.3390\/cancers14040921","article-title":"New insights into hormonal therapies in uterine sarcomas","volume":"14","author":"Maccaroni","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"3","key":"10.1016\/j.ijgc.2025.101992_bib74","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1002\/jso.24861","article-title":"Survival outcome of women with stage IV uterine carcinosarcoma who received neoadjuvant chemotherapy followed by surgery","volume":"117","author":"Matsuo","year":"2018","journal-title":"J Surg Oncol"},{"issue":"6","key":"10.1016\/j.ijgc.2025.101992_bib75","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1136\/ijgc-00009577-200411000-00008","article-title":"Adjuvant chemotherapy with cisplatin, ifosfamide, and doxorubicin followed by radiotherapy in localized uterine sarcomas: results of a case-control study with radiotherapy alone","volume":"14","author":"Pautier","year":"2004","journal-title":"Int J Gynecol Cancer"},{"issue":"2","key":"10.1016\/j.ijgc.2025.101992_bib76","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1006\/gyno.1996.0220","article-title":"Ifosfamide and doxorubicin in the treatment of advanced leiomyosarcomas of the uterus: a Gynecologic Oncology Group study","volume":"62","author":"Sutton","year":"1996","journal-title":"Gynecol Oncol"},{"issue":"12","key":"10.1016\/j.ijgc.2025.101992_bib77","doi-asserted-by":"crossref","first-page":"2824","DOI":"10.1200\/JCO.2002.11.050","article-title":"Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial","volume":"20","author":"Hensley","year":"2002","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ijgc.2025.101992_bib78","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1097\/01.coc.0000195088.28956.dd","article-title":"Phase II trial of gemcitabine as first line chemotherapy in patients with metastatic or unresectable soft tissue sarcoma","volume":"29","author":"Von Burton","year":"2006","journal-title":"Am J Clin Oncol"},{"issue":"21","key":"10.1016\/j.ijgc.2025.101992_bib79","doi-asserted-by":"crossref","first-page":"3144","DOI":"10.1200\/JCO.2006.09.7717","article-title":"Phase III trial of two investigational schedules of ifosfamide compared with standard-dose doxorubicin in advanced or metastatic soft tissue sarcoma: a European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study","volume":"25","author":"Lorigan","year":"2007","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.ijgc.2025.101992_bib80","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/S1470-2045(14)70063-4","article-title":"Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial","volume":"15","author":"Judson","year":"2014","journal-title":"Lancet Oncol"},{"issue":"10","key":"10.1016\/j.ijgc.2025.101992_bib81","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1200\/JCO.2014.58.3781","article-title":"Randomized phase III trial of gemcitabine plus docetaxel plus bevacizumab or placebo as first-line treatment for metastatic uterine leiomyosarcoma: an NRG Oncology\/Gynecologic Oncology Group study","volume":"33","author":"Hensley","year":"2015","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.ijgc.2025.101992_bib82","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/S1470-2045(15)70070-7","article-title":"Trabectedin in combination with doxorubicin for first-line treatment of advanced uterine or soft-tissue leiomyosarcoma (LMS-02): a non-randomised, multicentre, phase 2 trial","volume":"16","author":"Pautier","year":"2015","journal-title":"Lancet Oncol"},{"issue":"10","key":"10.1016\/j.ijgc.2025.101992_bib83","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/S1470-2045(17)30622-8","article-title":"Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial","volume":"18","author":"Seddon","year":"2017","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.ijgc.2025.101992_bib84","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s12916-017-0831-7","article-title":"Patterns of care and outcomes of patients with METAstatic soft tissue SARComa in a real-life setting: the METASARC observational study","volume":"15","author":"Savina","year":"2017","journal-title":"BMC Med"},{"issue":"13","key":"10.1016\/j.ijgc.2025.101992_bib85","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1001\/jama.2020.1707","article-title":"Effect of doxorubicin plus olaratumab vs doxorubicin plus placebo on survival in patients with advanced soft tissue sarcomas: the ANNOUNCE randomized clinical trial","volume":"323","author":"Tap","year":"2020","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.ijgc.2025.101992_bib86","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100209","article-title":"A single-arm multicentre phase II trial of doxorubicin in combination with trabectedin in the first-line treatment for leiomyosarcoma with long-term follow-up and impact of cytoreductive surgery","volume":"6","author":"Pautier","year":"2021","journal-title":"ESMO Open"},{"issue":"8","key":"10.1016\/j.ijgc.2025.101992_bib87","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/S1470-2045(22)00380-1","article-title":"Doxorubicin alone versus doxorubicin with trabectedin followed by trabectedin alone as first-line therapy for metastatic or unresectable leiomyosarcoma (LMS-04): a randomised, multicentre, open-label phase 3 trial","volume":"23","author":"Pautier","year":"2022","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1016\/j.ijgc.2025.101992_bib88","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1200\/JCO.2004.02.098","article-title":"Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy","volume":"22","author":"Garcia-Carbonero","year":"2004","journal-title":"J Clin Oncol."},{"issue":"9","key":"10.1016\/j.ijgc.2025.101992_bib89","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1023\/A:1012272007146","article-title":"Docetaxel as rescue medication in anthracycline- and ifosfamide-resistant locally advanced or metastatic soft tissue sarcoma: results of a phase II trial","volume":"12","author":"K\u00f6stler","year":"2001","journal-title":"Ann Oncol"},{"issue":"9","key":"10.1016\/j.ijgc.2025.101992_bib90","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1200\/JCO.2004.08.043","article-title":"Laboratory and clinical evidence of synergistic cytotoxicity of sequential treatment with gemcitabine followed by docetaxel in the treatment of sarcoma","volume":"22","author":"Leu","year":"2004","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.ijgc.2025.101992_bib91","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1200\/JCO.2005.01.180","article-title":"Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organization for Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial","volume":"23","author":"Le Cesne","year":"2005","journal-title":"J Clin Oncol"},{"issue":"19","key":"10.1016\/j.ijgc.2025.101992_bib92","doi-asserted-by":"crossref","first-page":"2755","DOI":"10.1200\/JCO.2006.10.4117","article-title":"Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected]","volume":"25","author":"Maki","year":"2007","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.ijgc.2025.101992_bib93","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.ygyno.2008.03.010","article-title":"Fixed-dose rate gemcitabine plus docetaxel as first-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II trial","volume":"109","author":"Hensley","year":"2008","journal-title":"Gynecol Oncol"},{"issue":"25","key":"10.1016\/j.ijgc.2025.101992_bib94","doi-asserted-by":"crossref","first-page":"4188","DOI":"10.1200\/JCO.2008.21.0088","article-title":"Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules","volume":"27","author":"Demetri","year":"2009","journal-title":"J Clin Oncol"},{"issue":"18","key":"10.1016\/j.ijgc.2025.101992_bib95","doi-asserted-by":"crossref","first-page":"2528","DOI":"10.1200\/JCO.2010.33.6107","article-title":"Randomized phase II study comparing gemcitabine plus dacarbazine versus dacarbazine alone in patients with previously treated soft tissue sarcoma: a Spanish Group for Research on Sarcomas study","volume":"29","author":"Garc\u00eda-Del-Muro","year":"2011","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.ijgc.2025.101992_bib96","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/S1470-2045(11)70230-3","article-title":"Activity of eribulin mesylate in patients with soft-tissue sarcoma: a phase 2 study in four independent histological subtypes","volume":"12","author":"Sch\u00f6ffski","year":"2011","journal-title":"Lancet Oncol"},{"issue":"9","key":"10.1016\/j.ijgc.2025.101992_bib97","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1634\/theoncologist.2011-0467","volume":"17","author":"Pautier","year":"2012","journal-title":"Oncologist"},{"issue":"3","key":"10.1016\/j.ijgc.2025.101992_bib98","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/S1470-2045(15)70031-8","article-title":"Interruption versus continuation of trabectedin in patients with soft-tissue sarcoma (T-DIS): a randomised phase 2 trial","volume":"16","author":"Le Cesne","year":"2015","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1016\/j.ijgc.2025.101992_bib99","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1200\/JCO.2015.62.4734","article-title":"Efficacy and safety of trabectedin or dacarbazine for metastatic liposarcoma or leiomyosarcoma after failure of conventional chemotherapy: results of a Phase III randomized multicenter clinical trial","volume":"34","author":"Demetri","year":"2016","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.ijgc.2025.101992_bib100","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.ygyno.2017.06.018","article-title":"Efficacy and safety of trabectedin or dacarbazine in patients with advanced uterine leiomyosarcoma after failure of anthracycline-based chemotherapy: subgroup analysis of a phase 3, randomized clinical trial","volume":"146","author":"Hensley","year":"2017","journal-title":"Gynecol Oncol"},{"issue":"11","key":"10.1016\/j.ijgc.2025.101992_bib101","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1038\/s41416-019-0462-1","article-title":"Eribulin versus dacarbazine in patients with leiomyosarcoma: subgroup analysis from a phase 3, open-label, randomised study","volume":"120","author":"Blay","year":"2019","journal-title":"Br J Cancer"},{"issue":"10028","key":"10.1016\/j.ijgc.2025.101992_bib102","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1016\/S0140-6736(15)01283-0","article-title":"Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial","volume":"387","author":"Sch\u00f6ffski","year":"2016","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.ijgc.2025.101992_bib103","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1093\/jjco\/hyw175","article-title":"Phase 2 study of eribulin in patients with previously treated advanced or metastatic soft tissue sarcoma","volume":"47","author":"Kawai","year":"2017","journal-title":"Jpn J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ijgc.2025.101992_bib104","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1186\/s12957-022-02781-1","article-title":"Stereotactic body radiotherapy for recurrent and oligometastatic soft tissue sarcoma","volume":"20","author":"Feng","year":"2022","journal-title":"World J Surg Oncol"},{"issue":"3","key":"10.1016\/j.ijgc.2025.101992_bib105","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.ygyno.2009.10.064","article-title":"Treatment of advanced uterine leiomyosarcoma with aromatase inhibitors","volume":"116","author":"O\u2019Cearbhaill","year":"2010","journal-title":"Gynecol Oncol"},{"issue":"5","key":"10.1016\/j.ijgc.2025.101992_bib106","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1002\/cncr.28476","article-title":"Phase 2 trial of aromatase inhibition with letrozole in patients with uterine leiomyosarcomas expressing estrogen and\/or progesterone receptors","volume":"120","author":"George","year":"2014","journal-title":"Cancer"},{"issue":"9829","key":"10.1016\/j.ijgc.2025.101992_bib107","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1016\/S0140-6736(12)60651-5","article-title":"Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"379","author":"van der Graaf","year":"2012","journal-title":"Lancet"},{"issue":"19","key":"10.1016\/j.ijgc.2025.101992_bib108","doi-asserted-by":"crossref","first-page":"3126","DOI":"10.1200\/JCO.2008.21.3223","volume":"27","author":"Sleijfer","year":"2009","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ijgc.2025.101992_bib109","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.ygyno.2016.03.024","article-title":"Outcome of uterine sarcoma patients treated with pazopanib: a retrospective analysis based on two European Organisation for Research and Treatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma Group (STBSG) clinical trials 62043 and 62072","volume":"142","author":"Benson","year":"2016","journal-title":"Gynecol Oncol"},{"issue":"8","key":"10.1016\/j.ijgc.2025.101992_bib110","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1056\/NEJMoa1714448","article-title":"Efficacy of Larotrectinib in TRK fusion-positive cancers in adults and children","volume":"378","author":"Drilon","year":"2018","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.ijgc.2025.101992_bib111","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1159\/000492597","article-title":"Differences in the efficacies of pazopanib and gemcitabine\/docetaxel as second-line treatments for metastatic soft tissue sarcoma","volume":"96","author":"Kim","year":"2019","journal-title":"Oncology"},{"issue":"12","key":"10.1016\/j.ijgc.2025.101992_bib112","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1016\/S1470-2045(16)30507-1","article-title":"Safety and efficacy of regorafenib in patients with advanced soft tissue sarcoma (REGOSARC): a randomised, double-blind, placebo-controlled, phase 2 trial","volume":"17","author":"Mir","year":"2016","journal-title":"Lancet Oncol"},{"issue":"21","key":"10.1016\/j.ijgc.2025.101992_bib113","doi-asserted-by":"crossref","first-page":"5233","DOI":"10.1158\/1078-0432.CCR-17-3766","article-title":"Safety and efficacy of anlotinib, a multikinase angiogenesis inhibitor, in patients with refractory metastatic soft-tissue sarcoma","volume":"24","author":"Chi","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.ijgc.2025.101992_bib114","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1093\/annonc\/mdt586","article-title":"Long-term responders and survivors on pazopanib for advanced soft tissue sarcomas: subanalysis of two European Organisation for Research and Treatment of Cancer (EORTC) clinical trials 62043 and 62072","volume":"25","author":"Kasper","year":"2014","journal-title":"Ann Oncol"},{"issue":"12","key":"10.1016\/j.ijgc.2025.101992_bib115","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1080\/0284186X.2017.1332779","article-title":"Treatment patterns and clinical outcomes with pazopanib in patients with advanced soft tissue sarcomas in a compassionate use setting: results of the SPIRE study","volume":"56","author":"Gelderblom","year":"2017","journal-title":"Acta Oncol"},{"key":"10.1016\/j.ijgc.2025.101992_bib116","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1186\/s12885-015-1160-x","article-title":"Efficacy of pazopanib monotherapy in patients who had been heavily pretreated for metastatic soft tissue sarcoma: a retrospective case series","volume":"15","author":"Yoo","year":"2015","journal-title":"BMC Cancer"},{"issue":"10043","key":"10.1016\/j.ijgc.2025.101992_bib117","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/S0140-6736(16)30587-6","article-title":"Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial","volume":"388","author":"Tap","year":"2016","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.ijgc.2025.101992_bib118","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1007\/s00280-014-2389-9","article-title":"A phase I study of olaratumab, an anti-platelet-derived growth factor receptor alpha (PDGFR\u03b1) monoclonal antibody, in patients with advanced solid tumors","volume":"73","author":"Chiorean","year":"2014","journal-title":"Cancer Chemother Pharmacol"},{"issue":"7","key":"10.1016\/j.ijgc.2025.101992_bib119","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1111\/cas.12444","article-title":"Phase I study of olaratumab in Japanese patients with advanced solid tumors","volume":"105","author":"Doi","year":"2014","journal-title":"Cancer Sci"},{"issue":"11","key":"10.1016\/j.ijgc.2025.101992_bib120","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1016\/S1470-2045(17)30624-1","article-title":"Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial","volume":"18","author":"Tawbi","year":"2017","journal-title":"Lancet Oncol"},{"issue":"17","key":"10.1016\/j.ijgc.2025.101992_bib121","doi-asserted-by":"crossref","first-page":"3285","DOI":"10.1002\/cncr.30738","article-title":"Immunotherapy with single agent nivolumab for advanced leiomyosarcoma of the uterus: results of a phase 2 study","volume":"123","author":"Ben-Ami","year":"2017","journal-title":"Cancer"},{"issue":"9","key":"10.1016\/j.ijgc.2025.101992_bib122","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1016\/S1470-2045(22)00392-8","article-title":"Durvalumab plus tremelimumab in advanced or metastatic soft tissue and bone sarcomas: a single-centre phase 2 trial","volume":"23","author":"Somaiah","year":"2022","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.ijgc.2025.101992_bib123","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S1470-2045(19)30153-6","article-title":"Axitinib plus pembrolizumab in patients with advanced sarcomas including alveolar soft-part sarcoma: a single-centre, single-arm, phase 2 trial","volume":"20","author":"Wilky","year":"2019","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.ijgc.2025.101992_bib124","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/S1470-2045(18)30006-8","article-title":"Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials","volume":"19","author":"D\u2019Angelo","year":"2018","journal-title":"Lancet Oncol"},{"issue":"11","key":"10.1016\/j.ijgc.2025.101992_bib125","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1001\/jamaoncol.2020.3689","article-title":"Assessment of doxorubicin and pembrolizumab in patients with advanced anthracycline-naive sarcoma: a phase 1\/2 nonrandomized clinical trial","volume":"6","author":"Pollack","year":"2020","journal-title":"JAMA Oncol"},{"issue":"2","key":"10.1016\/j.ijgc.2025.101992_bib126","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001561","article-title":"Nivolumab and sunitinib combination in advanced soft tissue sarcomas: a multicenter, single-arm, phase Ib\/II trial","volume":"8","author":"Martin-Broto","year":"2020","journal-title":"J Immunother Cancer"},{"issue":"3","key":"10.1016\/j.ijgc.2025.101992_bib127","doi-asserted-by":"crossref","first-page":"906","DOI":"10.3390\/cancers15030906","article-title":"SAINT: A phase I\/Expanded Phase II study using safe amounts of ipilimumab, nivolumab and trabectedin as first-line treatment of advanced soft tissue sarcoma","volume":"15","author":"Gordon","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"suppl 15","key":"10.1016\/j.ijgc.2025.101992_bib128","article-title":"Phase II study of eribulin and pembrolizumab in patients (pts) with metastatic soft tissue sarcomas (STS): report of LMS cohort","volume":"38","author":"Nathenson","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijgc.2025.101992_bib129","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2021.747650","article-title":"Activity of PD-1 inhibitor combined with anti-angiogenic therapy in advanced sarcoma: a single-center retrospective analysis","volume":"8","author":"You","year":"2021","journal-title":"Front Mol Biosci"},{"issue":"23","key":"10.1016\/j.ijgc.2025.101992_bib130","doi-asserted-by":"crossref","first-page":"6424","DOI":"10.1158\/1078-0432.CCR-21-2001","article-title":"Phase II study of pembrolizumab in combination with doxorubicin in metastatic and unresectable soft-tissue sarcoma","volume":"27","author":"Livingston","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"10","key":"10.1016\/j.ijgc.2025.101992_bib131","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1016\/S1470-2045(18)30438-8","article-title":"Trabectedin and olaparib in patients with advanced and non-resectable bone and soft-tissue sarcomas (TOMAS): an open-label, phase 1b study from the Italian Sarcoma Group","volume":"19","author":"Grignani","year":"2018","journal-title":"Lancet Oncol"},{"issue":"7","key":"10.1016\/j.ijgc.2025.101992_bib132","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1634\/theoncologist.2018-0448","article-title":"BRCA1\/2 functional loss defines a targetable subset in leiomyosarcoma","volume":"24","author":"Seligson","year":"2019","journal-title":"Oncologist"},{"issue":"25","key":"10.1016\/j.ijgc.2025.101992_bib133","doi-asserted-by":"crossref","first-page":"4154","DOI":"10.1200\/JCO.23.00402","article-title":"Phase II study of olaparib and temozolomide for advanced uterine leiomyosarcoma (NCI protocol 10250)","volume":"41","author":"Ingham","year":"2023","journal-title":"J Clin Oncol"},{"issue":"suppl 16","key":"10.1016\/j.ijgc.2025.101992_bib134","article-title":"Preliminary results of a phase IB study of olaparib with concomitant radiotherapy in locally advanced\/unresectable soft-tissue sarcoma from the French Sarcoma Group","volume":"40","author":"Sargos","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijgc.2025.101992_bib135","article-title":"LBA91 TOMAS2: a randomized phase II study from the Italian Sarcoma Group (ISG) of trabectedin plus olaparib (T+O) or trabectedin (T) in advanced, metastatic, or unresectable soft tissue sarcomas (STS) after failure of standard treatments","volume":"34","author":"D\u2019Ambrosio","year":"2023","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.ijgc.2025.101992_bib136","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/j.bpobgyn.2011.06.004","article-title":"Role of radiotherapy treatment of uterine sarcoma","volume":"25","author":"Sampath","year":"2011","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"key":"10.1016\/j.ijgc.2025.101992_bib137","article-title":"Retrospective analysis of BRCA-altered uterine sarcoma treated with poly(ADP-ribose) polymerase inhibitors","volume":"9","author":"Rao","year":"2025","journal-title":"JCO Precis Oncol"},{"issue":"4","key":"10.1016\/j.ijgc.2025.101992_bib138","doi-asserted-by":"crossref","first-page":"e55","DOI":"10.3802\/jgo.2022.33.e55","article-title":"Phase II study of niraparib in recurrent or persistent rare fraction of gynecologic malignancies with homologous recombination deficiency (JGOG2052)","volume":"33","author":"Asano","year":"2022","journal-title":"J Gynecol Oncol"},{"issue":"1","key":"10.1016\/j.ijgc.2025.101992_bib139","first-page":"53","article-title":"Pazopanib: approval for soft-tissue sarcoma","volume":"4","author":"Nguyen","year":"2013","journal-title":"J Adv Pract Oncol"},{"key":"10.1016\/j.ijgc.2025.101992_bib140","doi-asserted-by":"crossref","DOI":"10.1177\/20363613211034115","article-title":"Olaratumab\u2019s failure in soft tissue sarcoma","volume":"13","author":"Bou Zerdan","year":"2021","journal-title":"Rare Tumors"},{"issue":"20","key":"10.1016\/j.ijgc.2025.101992_bib141","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1200\/JCO.2011.37.4546","article-title":"Phase II trial of trastuzumab in combination with cytotoxic chemotherapy for treatment of metastatic osteosarcoma with human epidermal growth factor receptor 2 overexpression: a report from the Children\u2019s Oncology Group","volume":"30","author":"Ebb","year":"2012","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.ijgc.2025.101992_bib142","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.ygyno.2022.07.031","article-title":"Uterine sarcomas and rare uterine mesenchymal tumors with malignant potential. Diagnostic guidelines of the French Sarcoma Group and the Rare Gynecological Tumors Group","volume":"167","author":"Croce","year":"2022","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ijgc.2025.101992_bib143","doi-asserted-by":"crossref","DOI":"10.1177\/17588359231157645","article-title":"Uterine sarcomas: clinical practice guidelines for diagnosis, treatment, and follow-up, by Spanish group for research on sarcomas (GEIS)","volume":"15","author":"P\u00e9rez-Fidalgo","year":"2023","journal-title":"Ther Adv Med Oncol"},{"issue":"1","key":"10.1016\/j.ijgc.2025.101992_bib144","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.3802\/jgo.2020.31.e18","article-title":"Japan Society of Gynecologic Oncology 2018 guidelines for treatment of uterine body neoplasms","volume":"31","author":"Yamagami","year":"2020","journal-title":"J Gynecol Oncol"},{"key":"10.1016\/j.ijgc.2025.101992_bib145","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.ejogrb.2021.11.423","article-title":"British Gynaecological Cancer Society (BGCS) uterine cancer guidelines: recommendations for practice","volume":"270","author":"Morrison","year":"2022","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"10.1016\/j.ijgc.2025.101992_bib146","unstructured":"Treating uterine sarcoma. American Cancer Society. Accessed May 1, 2025. https:\/\/www.cancer.org\/cancer\/types\/uterine-sarcoma\/treating.html."},{"issue":"1","key":"10.1016\/j.ijgc.2025.101992_bib147","doi-asserted-by":"crossref","DOI":"10.3802\/jgo.2017.28.e12","article-title":"Practice guidelines for management of uterine corpus cancer in Korea: a Korean Society of Gynecologic Oncology Consensus Statement","volume":"28","author":"Lee","year":"2017","journal-title":"J Gynecol Oncol"},{"issue":"4","key":"10.1016\/j.ijgc.2025.101992_bib148","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.tjog.2016.04.033","article-title":"Uterine sarcoma part I-uterine leiomyosarcoma: the topic advisory group systematic review","volume":"55","author":"Wen","year":"2016","journal-title":"Taiwan J Obstet Gynecol"}],"container-title":["International Journal of Gynecological Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X25011120?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X25011120?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T03:15:01Z","timestamp":1788232501000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1048891X25011120"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":148,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S1048891X25011120"],"URL":"https:\/\/doi.org\/10.1016\/j.ijgc.2025.101992","relation":{},"ISSN":["1048-891X"],"issn-type":[{"value":"1048-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Uterine leiomyosarcoma","name":"articletitle","label":"Article Title"},{"value":"International Journal of Gynecological Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijgc.2025.101992","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 European Society of Gynaecological Oncology and the International Gynecologic Cancer Society. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"101992"}}